Creative Edge Nutrition, Inc. Letter to Shareholders

BEVERLY HILLS, CA and LAKESHORE, ON--(Marketwired - Mar 12, 2015) - Creative Edge Nutrition, Inc. (OTC PINK: FITX), a nutritional supplement company focusing on active lifestyles, announces a letter to its shareholders.

Dear Shareholders,

Over the past several weeks there has been much speculation regarding the status of CEN Biotech's application filed with Health Canada in September 2013 for licensure as a medicinal marijuana producer under Canada's MMPR program. As you may know, back on February 13, 2015, Health Canada issued the Company a "Letter of Intent to Deny" CEN Biotech's application, which letter was not received by CEN Biotech until February 18, 2015.

On March 11, 2015, CEO Bill Chaaban was personally served with a rejection notice from Health Canada, rejecting the application of CEN Biotech, and thereby denying the Company a license to produce medicinal marijuana under Canada's MMPR program. It is the Company's understanding that no internal investigation was conducted in denying the License, but rather resulted from mischaracterizations in the media intended to destroy CEN Biotech's reputation in the Court of public opinion. Due to CEN Biotech's never ending affinity for its loyal shareholders, it will not sit idly by and allow mischaracterizations and the dissemination of falsities to destroy the Company, but will continue to fight and utilize all legal means to continue to fight for licensure.

Specifically, due to the factual misrepresentations and fraud disseminated by certain news agencies and unscrupulous bashers seeking to soil the Company's reputation in the court of public opinion for the purpose of monetary and political gain, the Company has turned to the federal court of Canada for determination of whether CEN has complied with all of the requirements for license issuance. The determination regarding licensure must be dependent on the true facts and evidence, which until now, have seemingly gone unnoticed. CEN Biotech firmly believes that when the Court reviews the facts surrounding the application, and not fraudulent representations, unsupported statements and mischaracterizations, that it will quickly agree with our position. Facts cannot be ignored, and the facts surrounding the CEN Biotech application support issuance of a license.